SCHEMBL2498286

SCHEMBL2498286

CCNC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.73

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE P22303 12/20 0.73
BACE1 P56817 11/20 0.73
BCHE P06276 8/20 0.73
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
SIGMAR1 Q99720 2/20 0.61
HTR2A P28223 1/20 0.61
HTR2C P28335 1/20 0.61
HTR2B P41595 1/20 0.61
POLB P06746 2/20 0.60
SLC6A2 P23975 1/20 0.57
SLC6A4 P31645 1/20 0.57
SLC6A3 Q01959 1/20 0.57
DPP7 Q9UHL4 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2766858 0.98 ACHE (0.71) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL1781710 0.90 BCHE (0.75) ACHEBACE1BCHE
SCHEMBL1908453 0.90 BCHE (0.75) ACHEBACE1BCHE
SCHEMBL7504191 0.90 BCHE (0.75) ACHEBACE1BCHE
SCHEMBL28097152 0.90 ACHE (0.62) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL8408493 0.87 ACHE (0.69) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL14367985 0.85 ACHE (1.00) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL28787948 0.84 MEN1 (0.65) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL4902967 0.83 ACHE (0.64) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL360075 0.83 ACHE (0.68) ACHEBACE1BCHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974723-B Carboxamide ethylene anthracene compound, pharmaceutical composition containing same and application thereof 中国药科大学 2024-10-25 CN disclosed
CN-114685519-B Pyranocarbazole alkaloid derivatives and application thereof in treating Alzheimer's disease 中国医学科学院药物研究所 2023-09-26 CN disclosed
CN-115974723-A Carboxamide ethylene anthracenes compound, pharmaceutical composition containing same and application thereof 中国药科大学 2023-04-18 CN disclosed
CN-114685519-A Pyrano-carbazole alkaloid derivative and application thereof in treating Alzheimer's disease 中国医学科学院药物研究所 2022-07-01 CN disclosed
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-10167254-B2 IDO inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-01-01 US disclosed
EP-2976333-B1 QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS GENOSCIENCE PHARMA SAS (FR) 2018-08-08 EP disclosed
CN-108093636-A Indoleamine 2, 3-dioxygenase inhibitors for the treatment of cancer 百时美施贵宝公司 2018-05-29 CN disclosed
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-22 US disclosed
US-5621010-A ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-04-15 US disclosed
WO-1996018628-A1 ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 1996-06-20 WO disclosed
EP-0625507-A2 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO., LTD. (JP) 1994-11-23 EP disclosed
EP-0457686-B1 Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1994-08-03 EP disclosed
US-5214055-A Analgesics, psychological disorders, anxiolytic agents ADIR ET COMPAGNIE (FR) 1993-05-25 US disclosed
US-5189045-A Antiserotonine agent ADIR ET COMPAGNIE (FR) 1993-02-23 US disclosed
EP-0457686-A1 Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1991-11-21 EP disclosed
US-4711890-A TREATMENT OF ANXIETY STATES OR OF PULMONARY, RENAL, CIRCULATORY OF CARDIOVASCULAR DISORDERS RHONE-POULENC SANTE (FR) 1987-12-08 US disclosed
US-4684652-A TREATING ANXIETY OR CARDIOVASCULAR DISORDERS RHONE-POULENC SANTE (FR) 1987-08-04 US disclosed
US-4367232-A ANOREXIGENIC AGENTS,ANESTHETICS FORDONAL, S.A. (ES) 1983-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167254-B2 IDO inhibitors IDO1, IDO2, INMT ACHE 793/4885BACE1 1313/4885BCHE 1691/4885
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT ACHE 904/4885BACE1 2351/4885BCHE 1160/4885
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT ACHE 904/4885BACE1 2351/4885BCHE 1160/4885
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT ACHE 904/4885BACE1 2351/4885BCHE 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.